Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised Clinical Trial of Extended-Release Guanfacine Add-on Therapy in Alzheimer's Disease
2016-002598-36Phase 3Suspended
- Sponsor
- Imperial College London
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of guanfacine in Alzheimer's disease (AD) (2 arms), sponsored by Imperial College London. Primary endpoint: Cognition (ADAS-Cog). Started Jul 2016; status: suspended.
02
Drugs
guanfacine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2016-002598-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002598-36.